Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Molecular target based combinational therapeutic approaches in thyroid cancer.

Rajoria S, Suriano R, George AL, Kamat A, Schantz SP, Geliebter J, Tiwari RK.

J Transl Med. 2012 May 1;10:81. doi: 10.1186/1479-5876-10-81.

2.

Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer.

Rajoria S, Suriano R, George A, Shanmugam A, Schantz SP, Geliebter J, Tiwari RK.

PLoS One. 2011 Jan 18;6(1):e15879. doi: 10.1371/journal.pone.0015879.

3.

3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study.

Rajoria S, Suriano R, Parmar PS, Wilson YL, Megwalu U, Moscatello A, Bradlow HL, Sepkovic DW, Geliebter J, Schantz SP, Tiwari RK.

Thyroid. 2011 Mar;21(3):299-304. doi: 10.1089/thy.2010.0245. Epub 2011 Jan 22.

4.

3,3'-Diindolylmethane, a cruciferous vegetable derived synthetic anti-proliferative compound in thyroid disease.

Tadi K, Chang Y, Ashok BT, Chen Y, Moscatello A, Schaefer SD, Schantz SP, Policastro AJ, Geliebter J, Tiwari RK.

Biochem Biophys Res Commun. 2005 Nov 25;337(3):1019-25. Epub 2005 Oct 3.

PMID:
16219298
5.

A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes.

Qin C, Morrow D, Stewart J, Spencer K, Porter W, Smith R 3rd, Phillips T, Abdelrahim M, Samudio I, Safe S.

Mol Cancer Ther. 2004 Mar;3(3):247-60.

Supplemental Content

Loading ...
Support Center